Alimemazine, also known as trimeprazine, is a first-generation antihistamine developed in the mid-20th century and primarily used for allergic conditions, pruritus, and as a sedative orantiemetic. It works by blocking histamine H1 receptors in the central nervous system and peripheral tissues, reducing allergic symptoms such as itching, hives, and rhinitis. In addition to its antihistaminic effects, alimemazine has sedative and antiemetic properties, making it useful in treating insomnia, anxiety, or nausea in certain clinical settings. The drug is available in oral tablets, syrups, and injectable formulations, and is often reserved for short-term use due to sedation and anticholinergic side effects.
BRAND NAMES
Vallergan – commonly used oral tablets or syrup for allergy and sedation.
Noctamin – used for its sedative effects in some countries.
MECHANISM OF ACTION
Alimemazine (trimeprazine) is a first-generation antihistamine that exerts its effects primarily by blocking histamine H1 receptors in both the central nervous system and peripheral tissues. This antagonism reduces typical allergic symptoms such as itching, hives, and nasal congestion.
PHARMACOKINETICS
Absorption
Alimemazine is well absorbed after oral administration, with peak plasma concentrations typically reached within 1–2 hours. Food does not significantly affect its absorption, though taking it with meals may slightly delay the time to peak levels.
Distribution
Alimemazine has a moderate to high volume of distribution, approximately 3–5 L/kg, indicating that it distributes extensively from the plasma into tissues, including the central nervous system.
Metabolism
Alimemazine is extensively metabolized in the liver, primarily by hepatic enzymes including the cytochrome P450 system. Its metabolism produces several inactive metabolites, which are then eliminated from the body.
Elimination
Alimemazine and its metabolites are primarily excreted via the urine, with a smaller portion eliminated in the feces. The drug has an elimination half-life of approximately 4–6 hours, which supports multiple daily dosing for sustained therapeutic effect.
PHARMACODYNAMICS
Alimemazine (trimeprazine) exerts its therapeutic effects through antagonism of histamine H1 receptors, reducing allergic symptoms such as itching, hives, and nasal congestion. In addition to its peripheral antihistaminic activity, it has central nervous system effects, including sedation, anxiolysis, and antiemetic action, due to its ability to cross the blood-brain barrier and block central histamine and cholinergic pathways.
ADMINISTRATION
Alimemazine (trimeprazine) is administered either orally in the form of tablets or syrup, or parenterally via injection in hospital settings for more severe indications. Oral doses are typically given two to three times daily, with adjustments based on patient age, weight, and symptom severity, while injectable formulations are reserved for acute allergic reactions, agitation, or premedication before anesthesia.
DOSAGE AND STRENGTH
Alimemazine (trimeprazine) is available in oral tablets, syrup, and injectable formulations.
Oral tablets: Typically 5 mg, 10 mg, or 25 mg per tablet.
Syrup: Usually 1 mg/mL to 2 mg/mL concentrations.
Injectable solution: Commonly 2 mg/mL, used in hospital settings.
DRUG INTERACTIONS
Alimemazine (trimeprazine) can interact with several medications due to its central nervous system depressant and anticholinergic effects. Concomitant use with alcohol, benzodiazepines, barbiturates, or opioids may enhance sedation, drowsiness, or respiratory depression.
FOOD INTERACTIONS
Alimemazine (trimeprazine) can be taken with or without food, as food does not significantly affect its absorption or effectiveness. However, patients should avoid alcohol and other central nervous system depressants when taking the drug, as these can enhance sedation and drowsiness.
CONTRAINDICATIONS
Alimemazine (trimeprazine) is contraindicated in patients with a known hypersensitivity to the drug or any of its components. It should not be used in individuals with severe respiratory depression, coma, or significant central nervous system depression, as the sedative effects may worsen these conditions.
SIDE EFFECTS
Sedation and drowsiness – most common, dose-dependent
Dizziness or lightheadedness
Dry mouth – due to anticholinergic effects
Blurred vision – anticholinergic-related
Urinary retention – especially in elderly or patients with prostatic hypertrophy
Constipation – mild and infrequent.
TOXICITY
Alimemazine (trimeprazine) toxicity primarily arises from excessive central nervous system and anticholinergic effects. Overdose can lead to severe sedation, respiratory depression, hypotension, and coma, especially in children or elderly patients. Anticholinergic toxicity may cause dry mouth, urinary retention, blurred vision, and tachycardia.
